More on MYGN
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $5.76 |
|
|||
| Open | $5.72 | ||||
| 52 Wk High | $45.34 | ||||
| 52 Wk Low | $15.92 | ||||
| Day High | $5.86 | ||||
| Day Low | $5.60 | ||||
| P/E | 2.50 | ||||
| EPS | $2.33 | ||||
| Volume | 2,099,658 | ||||
- Myriad Genetics releases MRD cancer detection data at ESMO 2026
- Myriad Genetics Releases New MONSTAR-SCREEN-3 Data Demonstrating the Potential of Ultra-Sensitive MRD Detection in Colorectal and Pancreatic Cancers
- TD Cowen Reiterates Hold Rating on Myriad Genetics (MYGN)
- Myriad Genetics stock surges on $210M prenatal unit sale
- Piper Sandler Upgrades Myriad Genetics (MYGN) to Neutral
- Myriad Genetics to sell prenatal testing unit to Labcorp for $210M
- Form 8-K MYRIAD GENETICS INC For: Oct 19
- Myriad Genetics and Labcorp Announce Definitive Agreement for Myriad to Sell Prenatal Health Testing Business to Labcorp
- Myriad Genetics to Release Third Quarter 2026 Financial Results on November 4, 2026
- Myriad Genetics (MYGN) PT Raised to $4.50 at TD Cowen
Entities mentioned with MYGN
- Definitive Agreement | View Related Stories »
- Earnings | View Related Stories »
- FDA | View Related Stories »
- Twitter | View Related Stories »
- 13G | View Related Stories »
- JPMorgan | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Show More...
